HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260)
South Korea · Delayed Price · Currency is KRW 4,130.00
+186.83 (4.74%)
At close: Apr 1, 2026
HYUNDAI BIOLAND Revenue
In the year 2025, HYUNDAI BIOLAND had annual revenue of 130.51B KRW with 9.19% growth. HYUNDAI BIOLAND had revenue of 26.72B in the quarter ending December 31, 2025, with 3.19% growth.
Revenue
130.51B
Revenue Growth
+9.19%
P/S Ratio
0.92
Revenue / Employee
382.71M
Employees
341
Market Cap
120.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.51B | 10.99B | 9.19% |
| Dec 31, 2024 | 119.52B | 22.80B | 23.57% |
| Dec 31, 2023 | 96.72B | -2.43B | -2.45% |
| Dec 31, 2022 | 99.15B | -3.65B | -3.55% |
| Dec 31, 2021 | 102.80B | 13.90B | 15.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 257.56B |
| DongKoo Bio & Pharma | 238.39B |
| Daehan Nupharm | 202.40B |
| Kyung Dong Pharmaceutical | 193.64B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| KOREA PHARMA | 87.60B |
| Sam-A Pharm. | 76.66B |
| Polaris AI Pharma | 63.94B |